Journal article
Antimicrobial Activity of Chemokine CXCL10 for Dermal and Oral Microorganisms
Antibiotics (Basel), Vol.3(4), pp.527-539
10/23/2014
DOI: 10.3390/antibiotics3040527
PMCID: PMC4387564
PMID: 25859394
Abstract
CXCL10 (IP-10) is a small 10 kDa chemokine with antimicrobial activity. It is induced by IFN-γ, chemoattracts mononuclear cells, and promotes adhesion of T cells. Recently, we detected CXCL10 on the surface of the skin and in the oral cavity. In the current study, we used broth microdilution and radial diffusion assays to show that CXCL10 inhibits the growth of Escherichia coli, Staphylococcus aureus, Corynebacterium jeikeium, Corynebacterium striatum, and Candida albicans HMV4C, but not Corynebacterium bovis, Streptococcus mutans, Streptococcus mitis, Streptococcus sanguinis, Fusobacterium nucleatum, Aggregatibacter actinomycetemcomitans, Poryphromonas gingivalis, or C. albicans ATCC 64124. The reason for the selective antimicrobial activity is not yet known. However, antimicrobial activity of CXCL10 may be related to its composition and structure, as a cationic 98 amino acid residue molecule with 10 lysine residues, 7 arginine residues, a total net charge of +11, and a theoretical pI of 9.93. Modeling studies revealed that CXCL10 contains an α-helix at the N-terminal, three anti-parallel β-strands in the middle, and an α-helix at the C-terminal. Thus, CXCL10, when produced on the surface of the skin or in the oral cavity, likely has antimicrobial activity and may enhance innate antimicrobial and cellular responses to the presence of select commensal or opportunistic microorganisms.
Details
- Title: Subtitle
- Antimicrobial Activity of Chemokine CXCL10 for Dermal and Oral Microorganisms
- Creators
- Grant O Holdren - Division of Pharmaceutics and Translational Therapeutics, Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, The University of Iowa, Iowa City, IA 52242, USA; E-MailsDavid J Rosenthal - Dows Institute for Dental Research, College of Dentistry, The University of Iowa, Iowa City, IA 52242, USA; E-MailsJianyi Yang - Department of Computational Medicine and Bioinformatics, The University of Michigan, 100 Washtenaw Avenue, Ann Arbor, MI 48109, USA; E-MailsAmber M Bates - Dows Institute for Dental Research, College of Dentistry, The University of Iowa, Iowa City, IA 52242, USA; E-MailsCarol L Fischer - Dows Institute for Dental Research, College of Dentistry, The University of Iowa, Iowa City, IA 52242, USA; E-MailsYang Zhang - Department of Computational Medicine and Bioinformatics, The University of Michigan, 100 Washtenaw Avenue, Ann Arbor, MI 48109, USA; E-MailsNicole K Brogden - Division of Pharmaceutics and Translational Therapeutics, Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, The University of Iowa, Iowa City, IA 52242, USA; E-MailsKim A Brogden - Dows Institute for Dental Research, College of Dentistry, The University of Iowa, Iowa City, IA 52242, USA; E-Mails
- Resource Type
- Journal article
- Publication Details
- Antibiotics (Basel), Vol.3(4), pp.527-539
- DOI
- 10.3390/antibiotics3040527
- PMID
- 25859394
- PMCID
- PMC4387564
- NLM abbreviation
- Antibiotics (Basel)
- ISSN
- 2079-6382
- eISSN
- 2079-6382
- Publisher
- MDPI
- Language
- English
- Date published
- 10/23/2014
- Academic Unit
- Dermatology; Pharmaceutical Sciences and Experimental Therapeutics; Periodontics
- Record Identifier
- 9984025422102771
Metrics
22 Record Views